Tradjenta

Quote












Here's the explanation. Tradjenta is 3rd to market. Not only is it 3rd to market, but it's expensive. Not only is it 3rd to market and expensive, but the entire DPP-4 class are the least efficacious drugs in the entire diabetes market. It makes for the "perfect storm" for Tradgjenta--crappy efficacy, high cost, 3rd to market. Name any drug in any class that performed well with the same factors. Tradjenta is (and always was) dead.
 




Anonymous said:
Here's the explanation. Tradjenta is 3rd to market. Not only is it 3rd to market, but it's expensive. Not only is it 3rd to market and expensive, but the entire DPP-4 class are the least efficacious drugs in the entire diabetes market. It makes for the "perfect storm" for Tradgjenta--crappy efficacy, high cost, 3rd to market. Name any drug in any class that performed well with the same factors. Tradjenta is (and always was) dead.
Click to expand...

But it was on my PM.
 




Anonymous said:
Here's the explanation. Tradjenta is 3rd to market. Not only is it 3rd to market, but it's expensive. Not only is it 3rd to market and expensive, but the entire DPP-4 class are the least efficacious drugs in the entire diabetes market. It makes for the "perfect storm" for Tradgjenta--crappy efficacy, high cost, 3rd to market. Name any drug in any class that performed well with the same factors. Tradjenta is (and always was) dead.
Click to expand...

Well it seems that the BI - Lilly alliance is destined for utter failure, because the basal insulin products Lilly is developing are also dogs from a competitive advantage standpoint. I wonder if the glucose reuptake inhibitor from BI will be any good. Anyone have any insights on that one?
 




Top Bottom
Back
Quote